论文部分内容阅读
目的探索胃肠功能性疾病患者的应激反应水平和心理健康状况。方法回顾性研究2016年5—10月本院收治的胃肠功能性疾病患者74例作为研究组,选取同期住院治疗的非胃肠功能性疾病患者73例作为对照组,分析两组患者应激反应水平和心理健康状况差异。计量资料组间比较采用t检验,组内比较采用配对t检验,计数资料采用χ2检验,P<0.05为差异有统计学意义。结果治疗前,研究组餐后胀满、早饱感、食欲不振、恶心或呕吐发生率分别为32.43%、28.38%、44.59%、29.73%,均显著高于对照组的16.44%、5.48%、20.55%、15.07%,差异均有统计学意义(均P<0.05)。治疗前、治疗后3天,研究组的焦虑和抑郁水平分别为(36.47±5.34)、(35.32±6.17)、(28.36±5.04)、(28.29±5.58)分,均显著高于对照组的(33.26±5.47)、(32.28±6.36)、(23.51±4.26)、(24.85±5.24)分,差异均有统计学意义(均P<0.05)。研究组和对照组治疗后的焦虑和抑郁水平均显著低于治疗前,差异均有统计学意义(均P<0.05)。治疗前及治疗后1、3、5天研究组患者的血浆内皮素(endothelin,ET)和血管紧张素Ⅱ(angiotensinⅡ,AngⅡ)水平分别为(57.82±9.53)、(53.36±9.16)、(49.65±8.32)、(47.45±7.73)ng/L,均显著高于对照组的(49.47±7.45)、(47.34±7.27)、(45.43±6.57)、(42.61±6.07)ng/L,差异均有统计学意义(均P<0.05)。研究组患者躯体化、强迫症状、抑郁、焦虑、偏执和精神病性得分分别为(1.84±0.44)、(1.82±0.36)、(1.72±0.42)、(1.67±0.36)、(1.56±0.27)、(1.61±0.29)分,显著高于对照组的(1.57±0.36)、(1.69±0.34)、(1.56±0.34)、(1.52±0.32)、(1.38±0.26)、(1.35±0.27)分,差异均有统计学意义(均P<0.05)。结论胃肠功能性疾病患者的胃肠道不适感更多且强烈,焦虑和抑郁状况明显,应激反应水平较高,心理健康状况较差。
Objective To explore the stress response and mental health status of patients with gastrointestinal functional diseases. Methods A retrospective study of 74 patients with gastrointestinal dysfunction admitted to our hospital from May to October in 2016 was selected as the research group. 73 patients with non-gastrointestinal functional diseases hospitalized in the same period were selected as the control group. The stress Response levels and mental health differences. Measurement data were compared between groups using t test, the group was compared using paired t test, count data using χ2 test, P <0.05 for the difference was statistically significant. Results Before treatment, the incidence of postpartum bloating, early satiety, loss of appetite, nausea or vomiting were 32.43%, 28.38%, 44.59% and 29.73% in the study group, which were significantly higher than those in the control group (16.44% and 5.48% 20.55% and 15.07%, respectively (all P <0.05). Before treatment and three days after treatment, the levels of anxiety and depression in the study group were (36.47 ± 5.34), (35.32 ± 6.17), (28.36 ± 5.04) and (28.29 ± 5.58), respectively, which were significantly higher than those in the control group 33.26 ± 5.47), (32.28 ± 6.36), (23.51 ± 4.26) and (24.85 ± 5.24) respectively. There were significant differences between the two groups (all P <0.05). The levels of anxiety and depression in study group and control group after treatment were significantly lower than those before treatment (all P <0.05). The levels of endothelin (ET) and angiotensin Ⅱ (AngⅡ) in the study group were (57.82 ± 9.53), (53.36 ± 9.16) and (49.65 ± (P <0.05) ± (8.32) and (47.45 ± 7.73) ng / L in the control group were significantly higher than those in the control group (49.47 ± 7.45), (47.34 ± 7.27), (45.43 ± 6.57) and (42.61 ± 6.07) ng / Statistical significance (all P <0.05). The scores of somatization, obsessive compulsive disorder, depression, anxiety, paranoid and psychosis in study group were (1.84 ± 0.44), (1.82 ± 0.36), (1.72 ± 0.42), (1.67 ± 0.36) and (1.56 ± 0.27) (1.56 ± 0.34), (1.52 ± 0.32), (1.38 ± 0.26) and (1.35 ± 0.27) points in the control group (1.61 ± 0.29) The differences were statistically significant (all P <0.05). Conclusion Gastrointestinal discomfort is more and more intense in patients with gastrointestinal diseases, with obvious anxiety and depression, higher stress response and poor mental health status.